{"id":"W2794342932","doi":"10.1158/1538-7445.sabcs17-pd3-12","title":"Abstract PD3-12: <i>PIK3CA</i> alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Trastuzumab; Breast cancer; Oncology; Internal medicine; Clinical endpoint; Placebo; Population; Cancer; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041701,0.0007031534,0.001676026,0.0001975247,0.0003289416,0.001240643,0.0006052747,0.0007960409,0.006024279],"category_scores_gemma":[0.00418081,0.0002762369,0.002705792,0.0005245851,0.0006268821,0.000914104,0.00050041,0.002724651,0.0007109735],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005805032,"about_ca_system_score_gemma":0.0005967321,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003527564,"about_ca_topic_score_gemma":0.0009824127,"domain_scores_codex":[0.9983663,0.0009297896,0.0001690077,0.0002572622,0.000168834,0.0001087296],"domain_scores_gemma":[0.9974598,0.0007788073,0.0009354806,0.0002859739,0.0002492319,0.0002907934],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9253197,0.002613547,0.01680885,0.001635443,0.009820782,0.00009426228,0.00006286213,0.0009826374,0.004559196,0.0003838979,0.004878366,0.03284047],"study_design_scores_gemma":[0.7018794,0.1315875,0.1100539,0.0006817698,0.02828893,0.0007000072,0.0001559665,0.002098259,0.006687684,0.003011225,0.01473411,0.0001212222],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9616092,0.01784103,0.001105935,0.00170137,0.0003913255,0.001781256,0.008604277,0.00008149668,0.006884055],"genre_scores_gemma":[0.9874379,0.001946332,0.0007134887,0.001175394,0.0002346828,0.000922324,0.005748994,0.00001796187,0.001802916],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006024279,"threshold_uncertainty_score":0.0220539,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09401084786466163,"score_gpt":0.4463718082474957,"score_spread":0.3523609603828341,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}